title: A higher Charlson comorbidity index is related to more aggressive characteristics in de novo vesical tumours.
abstract: OBJECTIVE
  To analyze the relationship between the age--adjusted Charlson Comorbidity Index (aCCI) and pathological outcomes of transurethral resection of de novo bladder tumours (BT).
  
  
  METHODS
  Data from 208 patients who underwent a transurethral resection (TUR) of a de novo BT between 2007 and 2008 were collected. We recorded the following variables: age, sex, tobacco consumption, comorbidities assessed according to the ICCa (score and mortality rate), disease stage, tumour grade and risk of recurrence and progression. The relationship between the preoperative variables and the final pathological characteristics was analyzed. The multivariate study was conducted with the significant variables (P<.05) from the univariate analysis.
  
  
  RESULTS
  The mean age of the patients was 69.5 ± 12 years, and 77% were men. The mean ICCa was 6.4 ± 2.5. The final pathology results showed a Tx, T0, Ta, T1 and T ≥ 2 in 5.3, 6.7, 31.7, 26.9, and 28.8% of the cases, respectively. 33.3% of the tumours were low-grade and 66.7% were high-grade. 14.3% of the tumours were associated with carcinoma in situ. Among those non musculo-invasive bladder tumour (non-MIBT), 34.7% had a low risk of recurrence and progression, 18.1% had an intermediate risk and 47.2% had a high risk. The patients with a ICCa ≥ 5 had an increased number of MIBT (RR: 2.29; 1.1-4.8; P=.032), high-grade tumours (RR: 3.1; CI: 1.6-6; P=.001) and tumours with a high risk of recurrence and progression (RR: 2.9; CI: 1.4-5.9; P<.001).
  
  
  CONCLUSIONS
  The ICCa is related to the pathological characteristics of de novo BT. Patients with greater comorbidity can present more aggressive tumours. The ICCa could therefore be useful in clinical practice for identifying patients with worse prognosis.
authors.affiliation: Departamento de Urología, Hospital Clínic, Barcelona, España.
authors.forename: L
authors.initials: L
authors.lastname: Mateu
authors.affiliation: Departamento de Urología, Hospital Clínic, Barcelona, España. Electronic address: eduard.garcia.cruz@gmail.com.
authors.forename: E
authors.initials: E
authors.lastname: García-Cruz
authors.affiliation: Departamento de Urología, Hospital Clínic, Barcelona, España.
authors.forename: I
authors.initials: I
authors.lastname: Asiaín
authors.affiliation: Departamento de Urología, Hospital Clínic, Barcelona, España.
authors.forename: R
authors.initials: R
authors.lastname: Castañeda
authors.affiliation: Departamento de Urología, Hospital Clínic, Barcelona, España.
authors.forename: A
authors.initials: A
authors.lastname: Carrión
authors.affiliation: Departamento de Urología, Hospital Clínic, Barcelona, España.
authors.forename: J
authors.initials: J
authors.lastname: Huguet
authors.affiliation: Departamento de Urología, Hospital Clínic, Barcelona, España.
authors.forename: M J
authors.initials: MJ
authors.lastname: Ribal
authors.affiliation: Departamento de Urología, Hospital Clínic, Barcelona, España.
authors.forename: A
authors.initials: A
authors.lastname: Alcaraz
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000150:complications* / Q000473:pathology*
keywords: Bladder tumour; Charlson comorbidity index; Predicción de riesgo; Risk prediction; Tumor vesical; Índice de comorbilidad de Charlson